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Introduction: Array comparative genomic hybridisation (array CGH) is a powerful method that detects
alteration of gene copy number with greater resolution and efficiency than traditional methods. However,
its ability to detect disease causing duplications in constitutional genomic DNA has not been shown. We
developed an array CGH assay for X linked hypopituitarism, which is associated with duplication of
Xq26–q27.
Methods: We generated custom BAC/PAC arrays that spanned the 7.3 Mb critical region at Xq26.1–
q27.3, and used them to search for duplications in three previously uncharacterised families with X linked
hypopituitarism.
Results: Validation experiments clearly identified Xq26–q27 duplications that we had previously mapped
by fluorescence in situ hybridisation. Array CGH analysis of novel XH families identified three different
Xq26–q27 duplications, which together refine the critical region to a 3.9 Mb interval at Xq27.2–q27.3.
Expression analysis of six orthologous mouse genes from this region revealed that the transcription factor
Sox3 is expressed at 11.5 and 12.5 days after conception in the infundibulum of the developing pituitary
and the presumptive hypothalamus.
Discussion: Array CGH is a robust and sensitive method for identifying X chromosome duplications. The
existence of different, overlapping Xq duplications in five kindreds indicates that X linked hypopituitarism is
caused by increased gene dosage. Interestingly, all X linked hypopituitarism duplications contain SOX3.
As mutation of this gene in human beings and mice results in hypopituitarism, we hypothesise that
increased dosage of Sox3 causes perturbation of pituitary and hypothalamic development and may be the
causative mechanism for X linked hypopituitarism.
C
ongenital pituitary hormone deficiencies (hypopituitar-
ism) occur in approximately 1 in 4000 births,1 and have
many associated clinical features that reflect the
identity and degree of pituitary hormone deficiency. The
key phenotypic features (and their causes) are short stature
(growth hormone deficiency), infertility and delayed puberty
(gonadotropin deficiency), secondary hypothyroidism (thyr-
oid stimulating hormone deficiency), and poor stress
response (adrenocorticotropin deficiency). Many cases of
congenital pituitary hormone deficiency result from a failure
of the hormone secreting cell types in the pituitary to
differentiate. Alternatively, aberrant morphogenesis of the
hypothalamus, which controls pituitary hormone secretion
through the release of peptide signals, may also cause
hypopituitarism.
Most familial forms of congenital hypopituitarism are
autosomal recessive, and are associated with mutations in
transcriptional factors including HESX1, PROP1, and PIT1.2
However, an X linked form of hypopituitarism, (OMIM
312000) has also been reported.3–8 This disorder only affects
men, who display profound growth hormone deficiency from
birth, and most of whom also have deficiencies in other
anterior pituitary hormones. In some cases, patients are
deficient in all anterior pituitary hormones (panhypopituitar-
ism). Mild, non-specific mental retardation is also a feature
of most patients with X linked hypopituitarism.
Although the precise genetic basis for X linked hypopitui-
tarism remains to be identified, our previous studies indi-
cate that it results from increased gene dosage. Through
cytogenetic and fluorescence in situ hybridisation analysis of
a large Australian X linked hypopituitarism pedigree,6 we
mapped a 7.3 Mb interstitial duplication (previously esti-
mated to be 9 Mb) spanning Xq26.1–q27.3 that cosegregates
with the disease.8 Importantly, this duplication was shown to
be smaller and completely encompassed by a 13 Mb
interstitial duplication that we mapped in an independent
X linked hypopituitarism kindred.7 8 These data define a
7.3 Mb critical region for X linked hypopituitarism at Xq26.1–
q27.3.
Whilst fluorescence in situ hybridisation has proved to be a
useful technique for mapping X linked duplications, it has
several disadvantages including low throughput, a labour
intensive methodology and a necessity to use the patient’s
chromosomes or interphase nuclei. An alternative technology
that has recently been developed and that circumvents these
limitations is array comparative genomic hybridisation (array
CGH).9–14 This technique has been applied extensively in
cancer genomics and has proved to be a fast and reliable
method for detecting severalfold changes in gene copy
number within tumour samples.15 16 Furthermore, proof of
principle studies using chromosome specific arrays have
recently shown that array CGH is a sensitive and accurate
method for the high resolution mapping of heterozygous
autosomal deletions.17 18 However, the ability of array CGH to
detect autosomal and X chromosome duplications has not
been examined in detail.
Abbreviation: array CGH, array comparative genomic hybridisation
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Here we report the development of an array CGH
methodology for detecting duplications that span the X
linked hypopituitarism critical region. X linked duplications
were detected in three previously uncharacterised families
with X linked hypopituitarism. These data allow us to refine
the critical region for X linked hypopituitarism to 3.9 Mb and
support our hypothesis that increased gene dosage results in
X linked hypopituitarism. Expression analysis of critical
region genes showed that Sox3 is expressed in the infundi-
bulum of the developing pituitary, the presumptive hypo-
thalamus, and other regions of the central nervous system,
implicating this gene in the aetiology of X linked hypopitui-
tarism.
DATA ACCESS
The Ensemble Genome Browser (v16.33.1, 2 July 2003;
www.ensembl.org/) was used to obtain the chromosomal
position of clones and to identify candidate genes.
METHODS
Array comparative genomic hybridisation analysis
We produced arrays and performed hybridisation and
analysis using the MicroCASTer handheld micro-array
system and MicroHybridisation kit protocol (Schleicher and
Schuell). We prepared DNA from BAC and PAC genomic
clones using the modified QIAGEN protocol obtained from
the BACPAC Resources Center (http://bacpac.chori.org/).
10 mg of target BAC and PAC DNA were sonicated into 1.5–
15 kb fragments, ethanol precipitated and resuspended in
5 ml of 80% DMSO. DNA samples were printed manually onto
Superfrost Plus microscope slides (ESCO, Biolab Scientific).
One array, consisting of 24 clones, was printed per slide in
quadruplicate. Prior to hybridisation, DNA quality was tested
using POPO-3, a reversible DNA dye.
1.5 mg of test and reference DNA was labelled by nick
translation with CY3-dCTP or CY5-dCTP for 7 h at 15 C˚.
Samples were then left overnight at 4 C˚. Labelled test and
reference probes were combined with 50 mg of Cot-1 DNA,
precipitated with ethanol and dissolved in 10 ml of hybridisa-
tion mix containing 50% formamide, 10% dextran sulphate
and 26SSC. Samples were denatured at 95 C˚ for 5 min and
incubated at 37 C˚ for 1–2 h to block repetitive sequences.
Labelled probes were then added to slides, coverslips sealed
with rubber cement and placed in a humidified sealed
chamber at 37 C˚ for 48 hours. Following hybridisation, slides
were rinsed in 16SSC and washed in 16SSC twice for 10 min
at 60 C˚. After draining excess fluid, the slides were air dried
and scanned using the GenePix4000B scanner (Axon
Instruments). DNA clones were automatically located based
on their signal intensity. The CY3 and CY5 fluorescence
intensities for each spot were calculated and the local
background was subtracted. We used the median of the
ratios measurement for our studies, defined as the median of
pixel by pixel ratios of pixel intensities (GenePix Pro3). All
features had a signal intensity.30 (as defined by the %B635/
B532+2SD value14 17), which allowed us to obtain reliable
fluorescence values for every clone in the array. The four
fluorescence values for each clone were averaged and then
normalised using the average fluorescence values of the four
autosomal reference clones. This generated a normalised
fluorescence intensity ratio for each clone in the array. For all
arrays the standard deviations for each spot were calculated,
the upper and lower range of which are listed in the figure
legends. In all array experiments, the standard deviation was
,20%.
Fluorescence in situ hybridisation analysis
Fluorescence in situ hybridisation experiments were per-
formed using the method of Solomon et al8 using affected
male lymphoblast cell lines from the families with X linked
hypopituitarism described by Hol et al7 and Lagerstro¨m-
Ferme´r et al.6
X inactivation
This assay was performed using the androgen receptor
methylation assay on peripheral blood lymphocyte genomic
DNA as previously described.8
RT-PCR
Pituitary tissue was dissected from mouse embryos from
11.5 days after conception through to 17.5 days after
conception and RNA was extracted using TRIzol Reagent
(Gibco BRL). RNA was DNAase treated by incubation with
1 U DNAase I (Roche) per mg of RNA at 37 C˚ for 30 min.
10 mg of DNAase I-treated RNA was primed with hexamers
and reverse transcribed using AMV reverse transcriptase
(Roche). PCR was performed using 1/20 of the volume of the
RT reaction as template, 0.5 mM each primer, 0.2 mM
dNTPs, and 0.5 U Taq polymerase. All of the primers used
were designed to amplify under the following conditions:
94 C˚ for 30 s followed by 35 cycles of 94 C˚ for 30 s; 55 C˚ for
30 s; 72 C˚ for 30 s; followed by a 10 min extension at 72 C˚.
The sequences for forward and reverse primers are:
N AI526776, 59TCCCTTGGCAGGTCATTTTA, 59CTTTGCCTCC
TTCACGGTAG;
N BG920442, 59CAGAAAGAGTGGGACCTTGC, 59CAGCACC
TTCTCCAGATTCG;
N AI324160, 59AGAACCCCAAGATGCACAAC, 59CGGCGTTC
ATGTAGCTCTG;
N AW456110, 59TTTTTGTGGCAGACGTTGAT, 59TGTCTCCCA
ACAACCTCAGAT;
N BG077501, 59TTCCTGCTCAGCCTCTCTGT, 59CATCATCTTC
GTCGTCGGTA;
N AV256964, 59GCCATTACAAAAAGCCCAGA, 59GTGGCTGT
TGTGAGAATCCA.
In situ hybridisation
Mouse embryos were fixed overnight in 4% paraform-
aldehyde in phosphate buffered saline at 4 C˚ and then placed
in 20% sucrose in phosphate buffered saline overnight at 4 C˚.
Embryos were then embedded in OCT and 16 mM sections
prepared using a cryostat. Gene expression of Sox3 was
detected by hybridising digoxigenin labelled antisense ribo-
probes generated from the Sox3 IMAGE clone 388723
(GenBank). T3 RNA polymerase was used to generate the
sense (control) and T7 was used to generate the antisense
riboprobe. For the Atp11c gene, the primers were designed to
amplify a 427 bp fragment which was cloned into pCR II-
TOPO (Invitrogen). T7 RNA polymerase was used to generate
the sense (control) and SP6 RNA polymerase was used to
generate the antisense riboprobe. The procedure for in situ
hybridisation was performed as described previously.19
Clinical history
This study was approved by the Royal Children’s Hospital
Ethics in Research Committee and informed consent was
obtained from all participants.
Family A
Subject II.1 was born at 37 weeks gestation weighing 2.84 kg
to a 32 year old multiple gravida female (three miscarriages,
one ectopic pregnancy, two induced abortions, and two live
births) who was 162.5 cm tall (50th percentile). She smoked
cigarettes and took anticonvulsant medication during preg-
nancy for a grand mal seizure disorder. The Hispanic father
was of normal stature (1.68 m) and had no evidence of
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physical or mental abnormalities. APGAR scores were 8
(1 min) and 9 (5 min). As a neonate, II.1 had transient
feeding difficulties and bradycardia, a brief spell of hypo-
glycaemia, and was treated with antibiotics for group B
streptococcal infection. A computed tomography scan of the
brain was normal. He was referred on discharge from the
neonatal intensive care unit to receive physical therapy for
hypertonic posturing, which continued until 4K months of
age. Speech delay was diagnosed at 3 years, and at this time
his IGF-1 level was low (11 ng/ml; normal 22–87 ng/ml) and
his bone age was delayed (1 year 3 months, less than two
standard deviations). At age 4, his baseline IGF-1 level was
5 ng/ml (normal 22–87 ng/ml) and IGFBP-3 level was
0.5 mg/l (normal 1.4–3.0 mg/l). A clonidine stimulation test
was proposed at this time, but was not performed because of
missed appointments. Further testing at age 5 revealed low
baseline levels of IGF-1 (7 ng/ml, normal 17–248 ng/ml),
IGFBP-3 (0.8 mg/l, normal 1.4–3.0 mg/l) and thyroid stimu-
lating hormone (,0.04 mIU/l, normal 0.34–5.6 mIU/l),
prompting continued thyroxine treatment. At 7 years
8 months, his height was 1.02 m (24.37 standard devia-
tions), weight 18.6 kg. (22.00 standard deviations), and
head circumference 52.5 cm (50th percentile for age).
Endocrine testing at this time revealed low to normal
thyroxine levels (0.4 ng/dl, normal 0.16–1.6 ng/dl), low to
normal thyroid stimulating hormone levels (1.6 mIU/l,
normal 0.36–5.6 mIU/l) low to normal triiodothyronine levels
(2.6 pg/ml; normal 2.3–4.2 pg/ml), and normal baseline
cortisol levels (14 mg/dl; normal 8–24 mg/dl). His baseline
growth hormone level was 0.4 ng/ml and rose to 5.1 ng/ml
after vigorous exercise. Growth hormone therapy commenced
at 7 years 10 months, and resulted in a marked increase in
height growth rate (11.3 cm height gain over the first
13 months of treatment). His short stature is symmetric,
and there is no facial dysmorphism. His posture was lordotic.
His penile length was 5 cm (25th percentile) and testicular
volume was 2 cm3 (50th percentile). He is at the appropriate
grade level but has received some special education for
learning problems; however no formal IQ testing has been
performed.
Subject II.2 was the 2.66 kg product of a 38 week
pregnancy to his 33 year old mother. His African-American
father was of normal stature (1.63 m). He spent 3 weeks in
the neonatal intensive care unit for poor feeding, bradycardia,
and hypoglycaemia. A physical examination revealed normal
genitals. At age 2, his IGF-1 level was low (,10 ng/ml,
normal 20–126 ng/ml) and thyroid stimulating hormone and
thyroxine levels were borderline (thyroid stimulating
hormone=0.62 IU/ml; normal 0.32–5.0 IU/ml; thyroxine=
0.7 mg/ml; normal 0.7–1.8 mg/ml). Multiple tests in the
following years revealed consistently low baseline levels of
IGF-1 (12 ng/ml at age 4, 13 ng/ml at 5 years 10 months,
13 ng/ml at 6 years 6 months, normal 17–248 ng/ml) and
IGFBP-3 (1 mg/l at 3 years 3 months, 1 mg/l at 4 years,
normal 1.4–3.0 mg/l), indicating growth hormone deficiency.
Similarly, low to normal values for baseline thyroid stimulat-
ing hormone (0.58 IU/mL at 5 years 10 months, 0.79 IU/ml
at 6 years 3 months, normal 0.34–5.6 IU/ml), thyroxine
(0.5 ng/dl at 6 years 3 months, normal 0.6–1.6 ng/dl) and
triiodothyronine (2.5 pg/ml at 6 years 3 months, normal 2.3–
4.2 pg/ml) levels indicated borderline thyroid stimulating
hormone deficiency, and thyroxine therapy was initiated
shortly before age 4. Cortisol levels were normal (13 mg/dl at
6 years 3 months, 14 mg/dl at 6 years 3 months, normal 8.0–
24 mg/dl). An appointment for a clonidine stimulation test
was not kept. At age 6 years 8 months, his height was 1.00 m
(23.90 standard deviations), weight 17.5 kg (21.85 standard
deviations), and head circumference was 51 cm (25th
percentile). Penile length was 5 cm (25th percentile) and
testicular volume was 2.5 cm3 (50th percentile). On physical
examination, he has exaggerated lordosis, symmetric short
stature, and no facial dysmorphology. A markedly delayed
bone age was documented on a hand X ray (bone age 4 years,
chronological age 7K years). Growth hormone therapy was
initiated at 6 years 10 months, and resulted in a dramatic
increase in growth rate (11.9 cm height gain over the first
13 months of treatment). II.2 is at the appropriate grade level
but has received some special education for learning
problems and was diagnosed with attention deficit disorder.
Family B
Subject II.1 was born at 39 weeks gestation to a healthy 25
year old mother of normal height (1.65 m), weighing 3.47 kg.
Labour and delivery were uncomplicated and he went home
at one day old. At three days old, he presented to the hospital
with jaundice, hyperbilirubinaemia, and persistent hypo-
glycaemia. His random growth hormone level was ,1 ng/ml,
serum thyroxine level was 13.0 mg/dl, and 11 am cortisol level
was 16.9 mg/dl. He was sent home after an investigation for
sepsis yielded negative results. His hypoglycaemia was
apparently resolved by frequent feedings and careful mon-
itoring. At 12 months of age, he presented with hypoglycae-
mia and short stature; and was found to have a bone age of
9 months. At 20 months, he was seen by another endo-
crinologist for persistent hypoglycaemia, short stature, and
delayed growth. He was 73.6 cm tall, with a weight of 8.9 kg
and head circumference of 44.5 cm, all below the 5th
percentile for age. His bone age was 18 months. On physical
examination, it was noted that he had a microphallus and
undescended testes. Endocrine testing revealed an adequate
cortisol response to adrenocorticotropin (peak cortisol 21 mg/
dl). However, there was evidence for secondary hypothyroid-
ism (thyroid stimulating hormone ,5, total thyroxine 3.4 mg/
dl, repeat total thyroxine 4.9 mg/dl, normal 5–10 mg/dl). His
IGF-1 level was undetectable at ,0.2 U/ml. Two provocative
tests, one with L-dopa and another with glucagons, revealed
consistently undetectable levels of growth hormone after
maximum provocation (growth hormone levels ,0.5 ng/ml,
criterion for diagnosis is ,10 ng/ml). He also continued to
have hypoglycaemic episodes. A spontaneous hypoglycaemic
event with a serum glucose level of 34 mg/dl yielded a low
growth hormone level at 1.0 ng/ml and a normal cortisol level
of 25 mg/dl. He was then started on human growth hormone
and thyroid hormone replacement. Interestingly, he has had
persistent episodes of hypoglycaemia despite being on growth
hormone and thyroid hormone replacement. He was also
started on and maintained on cortisone acetate despite
‘‘adequate’’ cortisol levels for a period of time, which helped
his hypoglycaemia. II.1 was maintained on growth hormone
replacement until the age of 18 years. He is currently doing
well, having achieved a final height of 1.78 m. He is also on
thyroid hormone replacement.
II.2 was the 3.37 kg product of a normal, term pregnancy.
His mother was 27 years old. His father is 1.93 m and
healthy. He was referred to a paediatric endocrinologist at
5 months for failure to thrive, at which time a history of
neonatal hypoglycaemia (serum glucose 20 mg/dl) was
elicited and a small penis (2.5 cm) was noted. He was
started on L-thyroxine at 14 months for a thyroxine level of
6.3 mg/dl (thyroid stimulating hormone level, 0.5 mU/ml) and
growth hormone at 16 months for growth hormone levels of
,0.7 ng/ml after provocation with L-dopa/arginine and
glucagon. Growth hormone therapy was discontinued at
15K years at a height of 1.80 m, with a subsequent IGF-I
level of 69 ng/ml (reference range 286–627 ng/ml). Peak
cortisol levels after stimulation with Cortrosyn have consis-
tently been over 20 mg/dl. Low dose testosterone therapy was
prescribed for pubertal delay from 14K until 16K years,
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when early testicular enlargement was noted. At 18 years,
II.2 has 15–20 cm3 testicular volumes, Tanner V genitalia and
pubic hair, no facial hair, and a testosterone level of 358 ng/dl
(reference range 241–827 ng/dl). He has attended special
education classes since middle school. His maternal uncle,
I.3, is currently treated with L-thyroxine and hydrocortisone,
having had previous growth hormone therapy as a child.
Family C
Clinical details of this family have been described previously.4
RESULTS
Validation of array CGH assay
Fourteen BAC/PAC genomic clones spaced at regular inter-
vals within the 7.3 Mb X linked hypopituitarism critical
region at Xq26.1–q27.3 were selected for the array (clones 4–
17; table 1, fig 1). These clones contain approximately 30% of
the critical region sequence. Three BAC/PAC clones that map
proximal (clones 1–3) and distal (clones 18–20) to the 7.3 Mb
critical region were also included in the array, as were four
autosomal control BACs (clones 21–24). The chromosomal
location of all clones was confirmed by fluorescence in situ
hybridisation (data not shown).8 We first tested whether the
twofold difference in X chromosome dosage in XY males
against XX females could be detected using this array. As
shown in fig 1A, the average normalised fluorescence
intensity ratio for the X chromosome clones in this
experiment was 1.943. Therefore, the expected 1:2, male:fe-
male X chromosome copy number ratio was readily detected.
Next, we tested the ability of the array to detect interstitial X
chromosome duplications. Control male DNA was cohybri-
dised with DNA from an affected male from the X linked
hypopituitarism family described by Lagerstro¨m-Ferme´r et
al.6 The normalised fluorescence intensity ratio for X
chromosome clones that flank the 7.3 Mb duplication (clones
1–3 and 18–20) was 0.990 (fig 1B). In contrast, the
normalised fluorescence intensity ratio of clones located
within the 7.3 Mb duplication clones was 1.956, approxi-
mately double the value of non-duplicated clones. Array
CGH analysis of an affected male from the X linked
hypopituitarism family described by Hol et al7 produced
similar results, and indicated that this duplication encom-
passes the proximal clones 1–3 and the distal clone 18
(fig 1C). Fluorescence in situ hybridisation analysis of each of
these clones in the Hol et al7 male cell line confirmed their
duplicated status, as indicated by the two closely spaced
signals in interphase nuclei (fig 2A, B, C). In contrast, clones
1, 3, and 18 generated a single signal in interphase nuclei
from the Lagerstro¨m-Ferme´r et al6 family (fig 2 D, E, F).
These data demonstrate for the first time that array CGH is a
robust and sensitive method for identifying interstitial X
chromosome duplications.
Identification of novel duplications in families with X
linked hypopituitarism
Array CGH was then used to investigate whether duplicated
X chromosome material was present in two novel families
(families A and B) and one previously published family
(family C;4 fig 3 A, B, C) with X linked hypopituitarism. The
phenotypes of affected males in families A and B are
summarised in table 2. All affected males have profound
growth hormone deficiency, and some of them have thyroid
stimulating hormone deficiency. Mild developmental delay
may be present in these families, but has not been diagnosed.
Unaffected carrier females in families A and B showed
skewed X chromosome inactivation (approximately 80%), as
was observed in the Lagerstro¨m-Ferme´r et al6 and Hol et al7 X
linked hypopituitarism families (fig 3D).
Array CGH analysis of family A was performed by
comparing affected male DNA with normal male DNA, and
identical results were obtained for each affected male.
Affected males contain a novel Xq27 chromosome duplica-
tion that overlaps with the Lagerstro¨m-Ferme´r et al6 and Hol
et al7 X linked hypopituitarism duplications (fig 1D and
supplementary figure). The family A duplication includes
clones 11–20 which span a 5.3 Mb region at Xq27.2–q27.3.
The proximal breakpoint lies between clones 10 and 11,
which are linked by a single small clone, RPCI-3 523M5
(23.4 kb). The distal breakpoint is less well defined as the
duplication includes clone 20, which is the most distal X
Table 1 Address and position of array CGH BAC and PAC genomic clones
Clone number Clone name, library Chromosomal position (Mb) Accession number
1 RP1–136O17 125.9 Z72001
2 RP3–473B4 131.9 Z83826
3 RP11–481F23 132.6 AL357384
4 RP11–535K18 133.2 AL078638
5 RP11–528F22 133.6 AL445427
6 RP11–462H12 135.1 AL019212
7 RP11–389N12 135.3 AL359703
8 RP1–260J9 135.7 Z82193
9 RP1–227P17 136.2 Z81007
10 RP1–36J3 136.3 Z82975
11 RP1–93C23 136.4 AL008713
12 RP11–189F12 137.1 AL449184
13 RP11–51C14 137.5 AL121875
14 RP3–507I15 138.1 Z98950
15 RP1–85A12 139.0 AL049858
16 RP1–142F18 139.3 AL031073
17 RP3–357K22 140.1 AL022720
18 RP1–231L4 140.3 AL159988
19 RP11–514L15 141.0 AL022719
20 RP11–480M11 141.7 AC007015
21 RP11–89N12 (A) AL135920
22 RP11–91G21 (A) AC026304
23 RP11–3F4 (A) AC096886
24 RP11–71O21 (A) AC022291
Array CGH X chromosome clones (1–20) spanning Xq26–q28, listed in centromeric-telomeric order. Clones 21–
24 are autosomal (A).
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chromosome clone on the array. Based on these data, we
estimate that the family A duplication is at least 5.3 Mb and
includes Xq27.2–q27.3. Importantly, the position of the
proximal breakpoint in family A lies approximately 3.4 Mb
telomeric to the proximal breakpoint of the Lagerstro¨m-
Ferme´r et al6 7.3 Mb duplication (fig 1B). Therefore, a 3.9 Mb
interval at Xq27.2–q27.3 is duplicated in family A, the
Lagerstro¨m-Ferme´r et al6 family, and the Hol et al7 family,
which defines a reduced critical region for this disorder.
Array CGH analysis of families B and C also revealed
duplications in affected males (fig 1E, F). The proximal
breakpoint was localised in each family to an interval of
approximately 0.6 Mb between clones 3 (132.6 Mb) and 4
(133.2 Mb) that also contains the Lagerstro¨m-Ferme´r et al6
family breakpoint. The distal breakpoint for family B lies
between clones 19 and 20, indicating that the duplication
spans approximately 8.4 Mb. Identical results were obtained
for each affected male in family B. The family C duplication is
slightly smaller, and lies between clones 18 and 19. However,
because of the limited quantity of DNA that was available
from affected males in family C, we pooled an equal amount
of DNA from each available affected male (IV.1, IV.3, IV.4,
and IV.9) to obtain sufficient genomic material for analysis.
As the normalised fluorescence intensity ratio of clones 4 to
18 was approximately twice that of the autosomal control
BACs, it appears that all four affected males have the
duplication. To confirm the existence of this duplication, we
compared family C carrier female DNA (III.4) with a normal
male control. As shown in fig 1G, clones 4 to 18 all had
normalised fluorescence intensity ratios that were approxi-
mately three times the autosomal controls and therefore
provide additional evidence for the presence of a duplication
spanning these clones in this family. Therefore, family C
contains a novel Xq26.1–q27.3 duplication of approximately
7.7 Mb which overlaps with other X linked hypopituitarism
family duplications (fig 2D).
The critical region gene Sox3 is expressed in the
developing pituitary and hypothalamus
The identification of five different, overlapping duplications
in families with X linked hypopituitarism provides strong
evidence for increased gene dosage as the causative mechan-
ism for this disorder. The refined 3.9 Mb critical region for X
linked hypopituitarism contains 18 annotated transcripts
(table 3). Ten of these are published genes, and the
remaining eight putative genes are supported by multiple
ESTs, Unigene clusters, and gene prediction programs. As X
linked hypopituitarism is a congenital disease, we reasoned
that the causative gene or genes would be expressed in the
embryonic pituitary. As human embryonic pituitary tissue is
not readily available, and the genetic program that controls
pituitary morphogenesis is well conserved,20 21 we performed
an expression analysis using orthologous mouse genes. Nine
out of 18 genes had mouse orthologues that shared greater
than 80% sequence identity with the corresponding human
gene and were located on the X chromosome (table 2). Six of
Figure 1 Identification of Xq26–q27 duplications in families with X
linked hypopituitarism using array CGH. Each array CGH experiment
was conducted twice and the means of the eight replicates were
averaged. The relative positions of the X chromosome PAC/BAC clones
(1–20) are indicated at the bottom of the figure. Normalised
fluorescence intensity ratio values for X chromosome clones and
autosomal control clones (21–24) are shown in black and grey,
respectively. (A) Comparison of normal female versus normal male
DNA. (B) Lagerstro¨m-Ferme´r et al6 family X linked hypopituitarism male
versus normal male. (C) Hol et al7 male versus normal male. Note that
normalised fluorescence intensity ratio values are approximately 2 for
clones within the previously characterised Lagerstro¨m-Ferme´r et al6 and
Hol et al7 duplications. (D) Comparison of family A affected male (II.1)
versus normal male showing duplication of 5.3 Mb interval at Xq26–
q27 spanning clones 11–20. The average normalised fluorescence
intensity ratio for non-duplicated clones and duplicated X clones was
1.037 and 1.879, respectively. (E) Family B affected male (II.1) versus
normal male. An 8.4 Mb interstitial duplication spanning clones 4–19 is
present. The average normalised fluorescence intensity ratio for non-
duplicated and duplicated X clones was 0.988 and 1.879, respectively.
(F) Array CGH analysis of pooled DNA from family C affected males
reveals a 7.7 Mb duplication spanning clones 4–18. The average
normalised fluorescence intensity ratio for non-duplicated and
duplicated X clones was 1.02 and 1.897, respectively. (G)
Cohybridisation of family C carrier female DNA with normal male DNA.
The duplicated interval spans clones 4–18, as indicated by the
approximately threefold increase in normalised fluorescence intensity
ratio for these clones compared with autosomal control clones. Non-
duplicated X chromosome clones gave a normalised fluorescence
intensity ratio of approximately 2, reflecting the presence of two X
chromosomes. These data are consistent with array CGH analysis of
family C affected males shown in F. The reduced 3.9 Mb X linked
hypopituitarism critical region is indicated by the region between the
dotted lines. The standard deviation for all array CGH experiments was
well within the ¡0.2 inclusion threshold used by other researchers.14 17
The standard deviation ranges for each experiment were as follows: A,
0.0173–0.1290; B, 0.0165–0.1246; C, 0.0102–0.1606; D, 0.0124–
0.1312; E, 0.0151–0.140; F, 0.0157–0.1481; G, 0.0147–0.1351.
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these were screened for expression in the developing pituitary
using RT-PCR on mouse embryonic pituitary cDNA. The
integrity of the embryonic pituitary cDNA was tested and
confirmed using the pituitary specific markers Hesx1 and
Prop1 (data not shown). Only two were found to be expressed
in the developing pituitary; the transcription factor, Sox3,22 23
and the phospholipid transporting ATPase, Atp11c. To
determine the precise spatial and temporal regulation of
these genes in the developing pituitary, further expression
analysis was performed using in situ hybridisation. Gene
expression was also assessed in the developing central
nervous system, as many men with X linked hypopituitarism
exhibit mild mental retardation. At 12.5, 14.5, and 16.5 days
after conception, Atp11c expression was not detected in the
developing pituitary and hypothalamus by in situ hybridisa-
tion, suggesting that this gene may be expressed at very low
levels. In contrast, Sox3 expression was developmentally
regulated, as has been shown in previous expression
studies.23 24 At 10.5 days after conception, Sox3 is expressed
throughout the central nervous system and by 12.5 days after
conception is expressed in the dorsal aspect of the lateral
ventricle, the ventral diencephalon (including the presump-
tive hypothalamus), and the roof of the midbrain (fig 4A).
Importantly, in the developing pituitary, Sox3 is expressed at
high levels in the infundibulum at 11.5 days after conception
and 12.5 days after conception (fig 4A, B). At 13.5 days after
conception, Sox3 expression in the infundibulum is down
regulated and is maintained at a low level until 17.5 days
after conception (data not shown).
DISCUSSION
As X linked hypopituitarism does not appear to result from
gene mutation, standard mutation scanning methods cannot
be employed to identify the causative gene. X linked
hypopituitarism candidate genes, identified by their expres-
sion in the developing pituitary and hypothalamus, must be
tested functionally for their ability to generate a hypopitui-
tarism phenotype through overexpression in animal models
such as the mouse. As this process is laborious and time
consuming, we sought to reduce the size of the critical region
for X linked hypopituitarism through the identification of
additional X linked hypopituitarism duplications. Therefore,
we generated a high resolution X linked hypopituitarism
critical region array and performed a series of validation
experiments.
Array CGH analysis of males with X linked hypopituitarism
having Xq26–q27 duplications clearly showed the expected
normalised fluorescence intensity ratio value of <2 for BAC/
PAC clones located inside the duplicated region.7 8
Furthermore, analysis of affected males from previously
uncharacterised families with X linked hypopituitarism also
revealed a doubling of normalised fluorescence intensity ratio
Figure 2 Confirmation of array CGH results using interphase fluorescence in situ hybridisation analysis of affected male lymphoblast cell lines from
the Hol et al7 (A, B, C) and Lagerstro¨m-Ferme´r et al6 (D, E, F) X linked hypopituitarism families. Signals from ‘‘test’’ probes are in green and signals from
a duplicated Xq26.3 reference probe (RP1–260J9) are in red. Note that none of the test clones are contained within the Lagerstro¨m-Ferme´r et al6 family
duplication whereas all three clones are duplicated in the Hol et al7 cell line.
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values in consecutive BAC/PAC clones across Xq26–q27,
allowing us to define three novel duplications associated with
this disorder. Interestingly, when we cohybridised carrier
female DNA from families A and C with control male DNA,
we observed the expected 3:2 normalised fluorescence inten-
sity ratio values for duplicated BACs versus non-duplicated
Table 2 Summary of clinical features for families A and B
Patient Hormone deficiencies Mental retardation
Craniofacial
dysmorphology
Family A II.1 growth hormone, thyroid stimulating
hormone
No* No
Family A II.2 growth hormone No* No
Family B II.1 growth hormone, thyroid stimulating
hormone
No No
Family B II.2 growth hormone, thyroid stimulating
hormone
No* No
*Has received special education for learning problems.
Figure 3 Pedigrees for families A, B, and C. (A, B) Note that individual I.1 in family B is probably affected. (C) Family C was previously published by
Zipf et al.4 This revised pedigree has been extended to include four generations, containing five affected males. DNA used in this study was obtained
from affected individuals IV.1, IV.3, IV.4, and IV.9 and from the carrier female III.4. (D) Skewed X inactivation in family A and B carrier females. The
two androgen receptor alleles are indicated by the arrows on the right. UD, undigested; D, Hpa II digested.
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BACs on the X chromosome. Our array CGH method may
therefore also provide a rapid and definitive assay for
screening potential carrier females in X linked hypopituitar-
ism families. Furthermore, the ability to detect a 50% increase
in signal ratio intensity using this technique indicates that
array CGH may be a useful tool for detecting autosomal
duplications. This method may prove useful for screening
patient DNA for chromosomal imbalances such as trisomy 21
or regional duplications such as are observed in Charcot
Marie Tooth Syndrome25 and could be performed with
minimal DNA and in the absence of cell lines or chromo-
somes.
A major difference between our array and the majority of
published studies is the larger size of the features, which in
our study were approximately 500 mm in diameter.
Consequently, our arrays had a relatively large quantity of
target DNA, which may provide greater sensitivity by
increasing the signal to noise ratio. Furthermore, the
relatively small number of BAC/PAC clones on the array
and large quantity of target DNA printed onto the slide
enabled us to include 100% of the features for analysis. This is
a significant improvement over other studies in which 10–
20% of the features were excluded from the analysis due to
factors such as poor quality printing and low signal
intensity.11 13 15–17
The existence of different duplications spanning Xq27.2–
q27.3 in all five families with X linked hypopituitarism who
have been investigated to date provides strong support for
our hypothesis that increased dosage of a gene or genes
within this region is causative for X linked hypopituitarism.8
To identify X linked hypopituitarism candidate genes, we
performed an expression analysis of genes that map within
the newly defined 3.9 Mb critical region. The marked
congenital hypopituitarism in affected males indicates that
Figure 4 Sox3 is expressed in the developing pituitary and central nervous system. Panel A represents a sagittal section from a mouse embryo
12.0 days after conception showing strong expression in the infundibulum (IFN), the dorsal aspect of the lateral ventricle (LV), the ventral diencephalon
(VD), and the roof and wall of the midbrain (M). Panel B represents a sagittal section from a mouse embryo 11.5 days after conception, showing strong
expression in the IFN and presumptive hypothalamus (Hypo). No signal was detected in the Rathke’s pouch (RP).










ENSG00000181753 (novel) 136.2 nd ? ? ?
ENSG00000173954 (novel) 136.4 nd ? ? ?
Coagulation factor IX 136.6 F9 AI526776 87.9 no
Proto-oncogene DBL 136.6 MCF2 BG920442 85.5 no
Atpase, class VI, type 11C (NM_173694) 136.8 ATP11C AV256964 91.3 yes*
ENSG00000177219 (novel) 137.1 nd ENSG00000047561 ? ?
Transcription factor SOX3 137.5 SOX3 AI324160 94.1 yes
Cerebellar degeneration-related protein 137.8 CDR1 AW456110 94.1 no
SPANX family, member F1 138.0 SPANXF1 ? ? ?
ESNG00000184649 (Novel) 138.1 nd ? ? ?
Ribosomal Protein L44 138.2 O60801 ? ? ?
Leucine zipper, down regulated in cancer1 138.2 LDOC1 BG077501 81.3 no
SPANX family, member C1 138.3 SPANXC ? ? ?
ENSG00000171099 (novel) 138.3 nd ? ? ?
ENSG00000184242 (Q8N9U9) 138.5 nd ? ? ?
SPANX family, member A2 138.6 SPANXA2 ? ? ?
SPANX family, member E 138.7 SPANXE ? ? ?
Melanoma antigen, family E/C, 1 139.2 MAGEE1 MAGEC1 ENSMUSG00000045330 ? ?
*RT-PCR only; ?, unknown; nd, not determined.
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a severe defect in pituitary organogenesis occurs during the
commitment or differentiation of the five types of hormone
secreting cell. We screened six critical region genes for
expression in the pituitary during these developmental
stages, which occurs from 11.5 to 16.5 days after conception
in the mouse embryo.20 The Sox3 gene22 23 and the Atp11c gene
were the only genes found to be expressed in the developing
pituitary by RT-PCR analysis. In situ hybridisation analysis of
Atp11c however did not detect any expression in the embryo
at 12.5 days after conception, indicating that this gene is
expressed at very low levels. In contrast, Sox3 expression was
readily detected and was restricted to the developing pituitary
and central nervous system. Sox3 has not previously been
shown to be expressed in the pituitary and adds to the
growing list of transcription factors that are expressed in this
gland, many of which are critical for its development and
have conserved roles in mice and human beings.2 20 21
Furthermore, expression of Sox3 within the central nervous
system also implicates this gene in neuronal development or
function, which is impaired in the majority of males with X
linked hypopituitarism.6
Several genetic and classical embryological studies have
established that the infundibulum and ventral diencephalon
provide critical signals for the growth and differentiation of
the anterior pituitary primordium, Rathke’s pouch.26–29 In
addition, mutations that cause perturbation in hypothalamic
development, also result in hypopituitarism.30 A role for Sox3
in the development of the hypothalamic pituitary axis is
supported by a recent study by Laumonnier et al,31 who
identified SOX3 polyalanine expansion and deletion muta-
tions in two pedigrees with growth hormone deficiency and
mental retardation.31 32 The endocrine and neurological
features of affected males in these families fall within the
phenotypic spectrum of X linked hypopituitarism, although
the mild craniofacial anomalies are not typical of X linked
hypopituitarism. While the functional consequence of the
Laumonnier et al31 mutations is unclear, the phenotypic
overlap of affected males with increased dosage and
polyalanine expansion of SOX3 suggests a common mole-
cular pathology. These studies also suggest that the structural
components of the hypothalamic pituitary axis may be
sensitive to the levels of SOX3 protein during morpho-
genesis. This hypothesis is strongly supported by the
phenotype of Sox3 null and heterozygous mice, which
includes growth retardation, hypopituitarism, and significant
morphological defects in the pituitary and central nervous
system.33 34 Taken together, these data suggest that increased
dosage and consequent overexpression of SOX3 in the
infundibulum and central nervous system of human
embryos may be the causative mechanism for X linked
hypopituitarism. Generation of transgenic mice containing
additional copies of the SOX3 gene would provide a
method for testing the affect of increased SOX3 dosage and
may ultimately provide a mouse model for X linked
hypopituitarism.
The identification of Xq26–q27 duplications in five
independent X linked hypopituitarism kindreds indicates
that X linked hypopituitarism is a genetically homogeneous
condition. We have shown that array CGH is a robust and
sensitive assay for the detection and fine mapping of X
chromosome duplications. This technique will allow us to test
the possibility that sporadic cases of growth hormone
deficiency, which are significantly more common in males
than in females,35 are due to submicroscopic duplication of
Xq26–q27. Our initial array CGH analysis of five such male
patients indicates that Xq26–q27 duplications are not
present. However, we cannot exclude the possibility that
microduplications, too small to be detected by array CGH, are
present in these individuals.
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